![]() | ![]() |
Formats:
|
||||||||||||||||||
Copyright Dardente et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Implication of the F-Box Protein FBXL21 in Circadian Pacemaker Function in Mammals 1School of Biological Sciences, Aberdeen University, Aberdeen, Scotland, United Kingdom 2Institut de Neurosciences Cellulaires et Intégratives, Département de Neurobiologie des Rythmes, UMR7168, Strasbourg, France Sebastian D. Fugmann, Editor National Institute on Aging, United States of America * E-mail: h.dardente/at/abdn.ac.uk Conceived and designed the experiments: HD. Performed the experiments: HD JM JMF EC. Analyzed the data: HD JM EC DGH. Wrote the paper: HD DGH. ¤Current address: Department of Systems Biology, Graduate School of Pharmaceutical Science, Kyoto University, Kyoto, Japan Received July 8, 2008; Accepted October 5, 2008. Abstract In mammals, the circadian clock relies on interlocked feedback loops involving clock genes and their protein products. Post-translational modifications control intracellular trafficking, functionality and degradation of clock proteins and are keys to the functioning of the clock as recently exemplified for the F-Box protein Fbxl3. The SCFFbxl3 complex directs degradation of CRY1/2 proteins and Fbxl3 murine mutants have a slower clock. To assess whether the role of Fbxl3 is phylogenetically conserved, we investigated its function in the sheep, a diurnal ungulate. Our data show that Fbxl3 function is conserved and further reveal that its closest homologue, the F-Box protein Fbxl21, also binds to CRY1 which impairs its repressive action towards the transcriptional activators CLOCK/BMAL1. However, while Fbxl3 appears to be ubiquitously expressed, Fbxl21 expression is tissue-specific. Furthermore, and in sharp contrast with Fbxl3, Fbxl21 is highly expressed within the suprachiasmatic nuclei, site of the master clock, where it displays marked circadian oscillations apparently driven by members of the PAR-bZIP family. Finally, for both Fbxl3 and Fbxl21 we identified and functionally characterized novel splice-variants, which might reduce CRY1 proteasomal degradation dependent on cell context. Altogether, these data establish Fbxl21 as a novel circadian clock-controlled gene that plays a specific role within the mammalian circadian pacemaker. Introduction Endogenous circadian clocks generate rhythms of physiology and behaviour, and are synchronised to the environment through rhythmical stimuli, principally the light/dark cycle. These clocks allow organisms to anticipate and adapt to cyclical changes in environmental favourability. In mammals, the circadian clock relies on interlocked feedback loops in which a heterodimer of transcription factors, CLOCK/BMAL1 (CLK/BM1), drives transcription of Period1-3 (Per1-3) and Cryptochrome1-2 (Cry1-2) genes through E-Box cis-elements. The PER1-3 and CRY1-2 proteins then act as transcriptional inhibitors of CLK/BM1. Apart from Per1-3 and Cry1-2, the CLK/BM1 heterodimer acts on other genes, some of which are themselves clock components, such as the orphan nuclear receptors Rev-erb α or Ror α, while others are outputs from the clock, resulting in the regulation of cell- and tissue-specific processes [1]–[3]. The orphan nuclear receptors of the ROR and REV-ERB families act on DNA motifs known as ROREs to control rhythmic transcription of the Bmal1 gene, with activating and repressive action, respectively [4]–[7]. Other ancillary interlocked feedback loops, such as that through which REV-ERBs and RORs impinge on the transcriptional control of Rev-erb alpha [8]–[10] or that closed by the clock-controlled PAR-bZIP proteins through D-Boxes [11]–[13] add to the robustness of the clock mechanism [14]. Patterns of rhythmical transcription depend heavily on post-translational mechanisms operating within the circadian clock [3], [15]–[17]. Post-translational modifications of clock proteins include phosphorylation [16], SUMOylation [18] or acetylation [19], most of which are induced upon formation of heterodimers or larger protein complexes. These processes control intracellular trafficking of clock proteins, their functionality and ultimately their degradation. A timely orchestrated degradation of clock proteins is indispensable to the proper functioning of the clock as illustrated by the recently uncovered role for the F-Box protein Fbxl3. In mammals, the F-Box protein family comprises about 40 members, which direct ubiquitination and proteasome-mediated degradation of specific proteins through SCF (Spk/Cullin/F-Box protein) E3 ubiquitin ligase complex [20]–[22]. Accordingly, the SCFFbxl3 complex was recently shown to direct degradation of CRY1 and CRY2 proteins, with mutations in Fbxl13 leading to a slowed circadian clock in mice [23]–[25]. We sought to test whether the regulating effect of Fbxl3 was conserved in the diurnal sheep and investigate whether its closest homologue, Fbxl21 [26], is also involved in circadian function. Results and Discussion Ovine orthologues of Fbxl3 and Fbxl21 Cloning of ovine Fbxl3 generated a full-length (oFbxl3fl, GenBank EF643523) coding sequence (cds) of 1290 nucleotides (nt), giving a protein of 429 amino acids (Fig 1A/B
Sequence phylogeny analysis shows that Fbxl21 is the closest relative of Fbxl3 [26]. We therefore cloned a full-length cds for ovine Fbxl21 (oFbxl21fl, GenBank EU239380). This yielded a 1305 nt sequence giving a protein of 434 amino acids with a greater degree of inter-species divergence than was the case for Fbxl3 (94, 84 and 82% homology with bovine, mouse and human Fbxl21 respectively, Fig 1D Transcripts encoding truncated protein products such as oFbxl21sv have long been considered as erroneous splicing events but recent evidence indicates they may have specific functions [27], [30], [32]. Strikingly, conservation in splice-variant isoforms between mouse and human is very low, with estimates around 10–20% [28]–[29]. This might indicate meaningful evolutionary differences or, alternatively, reveal that splice-variants are merely a reflection of molecular noise generated by the splicing machinery [28]–[30]. In this context it is noteworthy that the same in-frame Fbxl3sv transcript characterized in the sheep is also present in the mouse (data not shown). Furthermore, we cloned a novel splice-variant for Fbxl21 in the mouse that encodes for a truncated protein product of a sequence reminiscent to that of oFbxl21sv (GenBank EU770600). These data demonstrate that AS is commonplace in the F-box protein family as emphasized elsewhere [26], which offers another putative layer of fine-tuning in the circadian clock. Furthermore, the fact that oFbxl3fl and oFbxl3sv are ubiquitously expressed while oFbxl21fl and oFbxl21sv display a clear-cut tissue-specific distribution strengthens the view that circadian clocks among tissues might have different characteristics, as previously suggested [7], [33]. Fbxl3 and Fbxl21 physically associate with Cry1 We used co-immunoprecipitation assays to determine whether sheep Fbxl3/21 orthologues bind to CRY1 in-vitro. We therefore cloned a full-length cds for ovine Cry1 (oCry1, GenBank EF494243) in a Flag-tagged expression vector while Fbxl3fl, Fbxl3sv, Fbxl21fl and Fbxl21sv were cloned in Myc-tagged expression constructs. These were co-transfected into COS7 cells in different combinations, prior to co-immunoprecipitation with beads coated with α-Myc antibodies followed by Western blotting (WB) with α-Myc or α-Flag antibodies (WB, Fig 2A
Differential effects of ovine Fbxl variants on CRY1 protein degradation We then assessed whether oFbxl proteins affect the degradation kinetics of molecular clock components. For this purpose full-length cds for orthologues of Clk (oClk, GenBank EU016223) and Bm1 (oBm1, GenBank EF494245) were cloned in the sheep. COS7 cells were co-transfected with oCry1, oBm1 and oClk in combination with the three Fbxl constructs which co-immunoprecipitated with oCRY1, and then treated with the protein synthesis inhibitor cycloheximide (CHX, 25 µg/ml) for 0–8 h. Proteins were extracted and relative levels were assessed by WB (Fig 3A
The Fbxl proteins had different effects on baseline oCRY1 and oBM1 levels immediately prior to CHX treatment (t = 0), but no impact on those for oCLK (Fig 3BTo normalise for these differing baseline levels, data were replotted as a fraction of t = 0 values for each expression vector combination (Fig 3C = 0 values after 8-h of protein synthesis blockade. A qualitatively similar but quantitatively more modest effect (non-significant, post-hoc test p<0.1) was seen for oFbxl21fl. By contrast, degradation rates for oCRY1 (but not oCLK or oBM1) in cells transfected with oFbxl3sv showed a trend towards reduction compared to controls (non-significant, post-hoc test p<0.1), confirming predictions that the truncated F-box motif in this protein leads to a protein stabilising effect.Collectively these data indicate that Fbxl21fl and Fbxl3sv, in addition to Fbxl3fl, govern the kinetics of degradation of CRY1. Fbxl3 and Fbxl21 modulate CRY1 suppression of CLK/BM1 induced E-box transactivation To investigate whether these differential effects on protein stability result in different clock gene function in vitro, we constructed a luciferase reporter with the promoter region of the sheep Rev-erb α gene (GenBank EF494248), a gene whose transcription is regulated through circadian E-boxes, responsive to CLK/BM1 [1]–[3]. We then performed further co-transfection experiments in which the impact of the various Fbxl on oCRY1-dependent transcriptional repression of oRev-erb α expression could be assessed. Similarly to results obtained in the mouse [25], this approach revealed that oCRY1 is a potent inhibitor of oCLK/oBM1-induced oRev-erb α transactivation, reducing expression by approximately 5-fold (Fig 4A
Rhythmical Fbxl21 expression is confined to the SCN within the hypothalamus Our RT-PCR screen showed that Fbxl3 is ubiquitously expressed while Fbxl21 has a highly tissue-specific expression pattern. We therefore wondered if Fbxl21 also shows localised expression within the hypothalamus. To address this, we performed radioactive in situ hybridisation in brain tissue from sheep sampled at ZT 4-6 and mice sampled around the clock using homologous probes. Remarkably, in the sheep hypothalamus we observed strong labelling within the SCN, which harbours the mammalian master clock, in a region overlapping with sites of arginine vasopressin (Avp, GenBank EU045357) and vaso-active intestinal polypeptide (Vip, GenBank EU016225) expression (Fig 5A
These data suggest that Fbxl21 may be a clock-controlled gene that plays a specific role in SCN pacemaker function. Fbxl21 is a clock-controlled gene The circadian pattern of Fbxl21 expression in the mouse SCN is reminiscent of that seen for other genes whose expression is driven by CLK/BM1 such as Per1 or Dbp. Analysis of the mFbxl21 gene promoter revealed no canonical E-Box (CACGTG) but 11 E' Boxes (CANNTG). Only 4 of these are conserved in the rat promoter (Fig 6A = 0.08) effect of DBP could be due to differences in binding affinities of the various PAR-bZIP proteins towards this D-Box [35]. Alternatively, transcriptional co-factors required for DBP might be missing in this cell type.
Taken together, these data suggest that the rhythmic expression of Fbxl21 in the mouse SCN derives from combined transactivation through E'boxes and a conserved D-Box element. Conclusion Altogether, these data indicate a broad conservation of transcriptional and post-translational mechanisms of the circadian clock between a nocturnal rodent and a diurnal ungulate and identify Fbxl21 as a new clock component whose expression is driven by the core-clock. The functional characterization of new splice-variants also suggests that AS might be an important mechanism to fine-tune the clock. This idea is also supported by data for Bmal2 [34], [36], Timeless [37] or the finding of a temperature-dependent splicing of the Period gene in Drosophila [38]. Since Fbxl21 directs degradation of CRY1 and displays strong and specific rhythmic circadian expression within the central pacemaker of the SCN, we suggest that Fbxl21 stands at a crucial crossroads between activation and repression in central clocking (Fig 7
Materials and Methods Sheep tissue collection Hypothalamic blocks for in-situ hybridisation and central tissue samples were obtained from Blackface sheep killed at a local slaughterhouse (McIntosh Donald, Portlethen, UK). Sheep were killed by the pneumatic captive bolt gun method carried out by a licensed person. Peripheral tissues were sampled from Soay rams killed by an overdose of barbiturate (Euthatal; Rhone Merieux, Essex, UK) administered intravenously. All experiments were performed in accordance with Home Office (UK) legislation and approved by University of Edinburgh Local Ethics Committee. Tissues were rapidly dissected out, frozen onto dry ice and kept at −80°C until sectioning or RNA extraction. Mouse tissue collection Adult male Swiss mice (Charles River, Lyon, France) were kept in a 12-h light/dark cycle (LD) or transferred to constant darkness (DD) for 2 days. After mice were deeply anesthetized with isoflurane and decapitated, brains were removed, frozen and cut in 20-µm coronal sections at the level of the suprachiasmatic region. Five mice were killed every 4 h throughout the LD cycle (expressed in zeitgeber time, ZT0 being the time of lights on) or throughout the DD cycle (expressed in circadian time, CT0 being defined as the projected time of lights on). Experiments were performed in accordance with the rules of the European Committee Council directive of November 24, 1986 (86/609/EEC) and the French Department of Agriculture (license n°67–88 to E.C.). Cloning DNA extraction was done with a QIAamp DNA mini kit (Qiagen). RNA extraction was performed using Tri-reagent (Sigma) according to the manufacturer's protocol, and cDNA synthesis was carried out using a reverse transcription kit (Qiagen). When sheep EST were not available, ClustalW alignments of mammalian sequences were performed in order to identify conserved regions suitable for primer design (primers from MWG Biotech, Germany). PCR was done with Platinum Taq Hifi (Invitrogen) according to the manufacturer's protocol. Following agarose gel electrophoresis, PCR fragments of the expected sizes were extracted using a gel extraction kit (Qiagen) and cloned in pGEM-T easy vector (Promega). Four to six positive clones were sequenced (MWG, United Kingdom), and the sequences deposited in GenBank. To generate expression constructs, a second round of PCR was performed using primers flanked by adequate restriction sites and the pGEM-T clone as template. PCR fragments were extracted as described above, digested by the adequate restriction enzymes, purified with a PCR purification kit (Qiagen) and cloned in the expression vector backbone. Two different expression vectors with either a Flag or a 5X-Myc tag were used. To generate promoter reporter constructs, a strategy identical to that described above was applied. All fragments were cloned into the pGL3 basic backbone (Promega) digested with the appropriate restriction enzymes. Sequencing was performed to check accuracy of the re-amplified cloned fragments. All primer sequences and constructs are available upon request. Cell culture, transfection and luciferase assay COS-7 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 1% Pen/Strep mix and sodium pyruvate in a humidified atmosphere with 5% CO2 at 37°C. Cells were plated in either 6-well or 24-well plates (for WB or luciferase assay, respectively), and transfected with GeneJuice (Novagen). For luciferase assays, expression vectors were used at different doses depending on the experiment. Promoter reporter constructs and β-galactosidase reporter construct were used at 50 ng/well. Total transfected DNA amount was set to an equal amount between all conditions by addition of the corresponding empty vector. Luciferase assay was performed on the day following transfection. Briefly, cells were rinsed twice in cold PBS and lysed for 15 min in lysis buffer (25 mM Tris, 2 mM EDTA, 1 mM DTT (dithiothreitol), 10% glycerol and 1% Triton X-100). The luciferase assay was performed using a Luciferase assay system kit (Promega) and a Lumicount microplate luminometer (Packard). Results were normalised to β-galactosidase activity. Data (in relative luminescence units) represent fold induction once normalised to β-galactosidase. Experiments were repeated three to five times, each condition in triplicate. For WB experiments, variable amounts of DNA were transfected, never exceeding 4 µg/well. Experiments were done at least in triplicate. Western blot and immunoprecipitation Cells were plated in 6-well plates and transfected as described above. For protein synthesis inhibition experiments, 25 µg/ml cycloheximide (CHX; Sigma) was added 24 h post-transfection for 8, 2 or 0 h prior to harvesting. Cells were rinsed twice in cold PBS, resuspended in RIPA buffer (50 mMTris-HCl, pH 8, 150 mM NaCl, 1% Nonidet P40, 0.5% Na-deoxycholate, 0.1% SDS, 0.5 mM DTT, 1 mM PMSF and a cocktail of protease inhibitors (Complete Mini; Roche) and incubated for 30 min on ice. After vortexing, the extract was centrifuged for 1 min at 16000 g and supernatants used for Western blot (WB) or kept at −80°C. For immunoprecipitation assay cells were harvested 48 h post-transfection in IP buffer (150 mM NaCl, 5 mM EDTA, 0.5% Nonidet P40, 50 mM Tris, pH 7.8, 1 mM PMSF and a cocktail of protease inhibitors (Complete Mini; Roche). An aliquot of supernatant was kept as input for western-blot analysis while the rest was incubated overnight at 4°C with anti-Myc affinity resin (Sigma) in IP buffer. The beads were then washed twice with IP buffer, resuspended in Laemmli buffer (50 mM Tris/HCl pH 6.8, 2% SDS, 0.1% Bromophenol Blue, 10% glycerol and 100 mM DTT), denatured at 95°C for 5 min and the supernatant was resolved on a 6% or 12% SDS polyacrylamide gel. Nitrocellulose membranes (Amersham) were then probed with antibodies directed against Myc (Roche) or Flag (Sigma). Anti-mouse horseradish peroxidase-conjugated antibody (Sigma) and the ECL® (enhanced chemiluminescence) detection reagent (Amersham) were used for revelation using Hyperfilm ECL (Amersham). RT-PCR on tissues RT-PCR was performed as described in the tissue collection and cloning section. Co-amplification of an 879 bp fragment of oCKIδ was used as a positive control. Omission of cDNA in the PCR mix was used as a negative control. Initial screening for Fbxl3 was performed using oligos O47C (GGGGTAATCTCCTTCAGG) and O48C (CTAGGACTTTGAGCGAGG) yielding 471 and 327 nt PCR fragments for Fbxl3fl and Fbxl3sv, respectively. Another PCR was performed using oligos O51C (GCAACTGGAACCAGGTGG) and O52C (GGAAGTGAGTCTGTCCTGG) yielding a 474 nt PCR product for Fbxl3sv only since O51C spans the splicing junction (the sequence corresponding to O51C in Fbxl3fl being GCAACTGGAACCAGGTAT prevents complete hybidization of the oligo hence polymerisation). Confirming specificity of the approach, no PCR product was obtained with O51C/O52C when the Fbxl3fl expression vector was used as a template while the expected 474 nt product was readily amplified from the Fbxl3sv expression construct. PCR screening for Fbxl21 was performed using oligos O49C (CCATCTCCAGTATGTCAGC) and O50C (ATGCCAGTTCTCTCAGACC) yielding 386 and 298 nt PCR fragments for Fbxl21fl and Fbxl21sv, respectively. In-situ hybridisation Complete cds for the ovine arginine-vasopressin (Avp) and vasoactive intestinal polypeptide (Vip) were cloned and deposited in GenBank. Homologous probes used in this paper are as follows: oFbxl3 covers nt 110–580 of EF643523, oFbxl21 covers nt 342–709 of EU239380, oAvp covers nt 1–501 of EU045357, oVip covers nt 1–513 of EU016225, mFbxl3 covers nt 450–1175 of NM_015822, mFbxl21 covers nt 905–1656 of NM_178674. Hypothalamic blocks for in situ hybridisation were cut into 20 µm sections using a cryostat, and thaw-mounted onto poly-lysine and gelatin coated slides. Radioactive cRNA riboprobes were prepared by plasmid linearisation and in vitro transcription reactions including 35S-UTP (Perkin-Elmer). Sections were hybridized overnight at 60°C with 5.105 cpm of probe per slide, subjected to RNaseA digestion and stringency washes in sodium citrate buffer to remove nonspecific probe hybridisation. Slides were then dehydrated in graded ethanol solutions and exposed to an autoradiographic film (Kodak) for 4 days. Statistics Data were analysed (Sigma-stat, Jandel Scientific) by one-way or two-way ANOVA followed, when appropriate, by the Student-Newman–Keuls post-hoc test. Significance was set at P<0.05. Footnotes Competing Interests: The authors have declared that no competing interests exist. Funding: HD and DGH are supported by the UK Biotechnology and Biological Sciences Research Council for continuing support. JM and EC are supported by grants from the Agence Nationale pour la Recherche ‘Jeunes Chercheurs/Jeunes Chercheuses’ and Centre National de la Recherche Scientifique. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. References 1. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002;418:935–941. [PubMed] 2. Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. Hum Mol Genet. 2006;15 Spec No 2:R271–7. [PubMed] 3. Dardente H, Cermakian N. Molecular circadian rhythms in central and peripheral clocks in mammals. Chronobiol Int. 2007;24:195–213. [PubMed] 4. Preitner N, Damiola F, Lopez-Molina L, Zakany J, Duboule D, et al. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell. 2002;110:251–260. [PubMed] 5. Sato TK, Panda S, Miraglia LJ, Reyes TM, Rudic RD, et al. A functional genomics strategy reveals rora as a component of the mammalian circadian clock. Neuron. 2004;43:527–537. [PubMed] 6. Akashi M, Takumi T. The orphan nuclear receptor RORalpha regulates circadian transcription of the mammalian core-clock Bmal1. Nat Struct Mol Biol. 2005;12:441–448. [PubMed] 7. Guillaumond F, Dardente H, Giguere V, Cermakian N. Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. J Biol Rhythms. 2005;20:391–403. [PubMed] 8. Adelmant G, Begue A, Stehelin D, Laudet V. A functional Rev-erb alpha responsive element located in the human Rev- erb alpha promoter mediates a repressing activity. Proc Natl Acad Sci U S A. 1996;93:3553–3558. [PubMed] 9. Raspe E, Mautino G, Duval C, Fontaine C, Duez H, et al. Transcriptional regulation of human rev-erbalpha gene expression by the orphan nuclear receptor retinoic acid-related orphan receptor alpha. J Biol Chem. 2002;277:49275–49281. [PubMed] 10. Delerive P, Chin WW, Suen CS. Identification of Reverb(alpha) as a novel ROR(alpha) target gene. J Biol Chem. 2002;277:35013–35018. [PubMed] 11. Yamaguchi S, Mitsui S, Yan L, Yagita K, Miyake S, et al. Role of DBP in the circadian oscillatory mechanism. Mol Cell Biol. 2000;20:4773–4781. [PubMed] 12. Mitsui S, Yamaguchi S, Matsuo T, Ishida Y, Okamura H. Antagonistic role of E4BP4 and PAR proteins in the circadian oscillatory mechanism. Genes Dev. 2001;15:995–1006. [PubMed] 13. Ripperger JA, Shearman LP, Reppert SM, Schibler U. CLOCK, an essential pacemaker component, controls expression of the circadian transcription factor DBP. Genes Dev. 2000;14:679–689. [PubMed] 14. Ueda HR, Hayashi S, Chen W, Sano M, Machida M, et al. System-level identification of transcriptional circuits underlying mammalian circadian clocks. Nat Genet. 2005;37:187–192. [PubMed] 15. Lowrey PL, Shimomura K, Antoch MP, Yamazaki S, Zemenides PD, et al. Positional syntenic cloning and functional characterization of the mammalian circadian mutation tau. Science. 2000;288:483–492. [PubMed] 16. Lee C, Etchegaray JP, Cagampang FR, Loudon AS, Reppert SM. Posttranslational mechanisms regulate the mammalian circadian clock. Cell. 2001;107:855–867. [PubMed] 17. Gallego M, Virshup DM. Post-translational modifications regulate the ticking of the circadian clock. Nat Rev Mol Cell Biol. 2007;8:139–148. [PubMed] 18. Cardone L, Hirayama J, Giordano F, Tamaru T, Palvimo JJ, et al. Circadian clock control by SUMOylation of BMAL1. Science. 2005;309:1390–1394. [PubMed] 19. Hirayama J, Sahar S, Grimaldi B, Tamaru T, Takamatsu K, et al. CLOCK-mediated acetylation of BMAL1 controls circadian function. Nature. 2007;450:1086–1090. [PubMed] 20. Cenciarelli C, Chiaur DS, Guardavaccaro D, Parks W, Vidal M, et al. Identification of a family of human F-box proteins. Curr Biol. 1999;9:1177–1179. [PubMed] 21. Kipreos ET, Pagano M. The F-box protein family. Genome Biol. 2000;1:REVIEWS3002. [PubMed] 22. Winston JT, Koepp DM, Zhu C, Elledge SJ, Harper JW. A family of mammalian F-box proteins. Curr Biol. 1999;9:1180–1182. [PubMed] 23. Busino L, Bassermann F, Maiolica A, Lee C, Nolan PM, et al. SCFFbxl3 controls the oscillation of the circadian clock by directing the degradation of cryptochrome proteins. Science. 2007;316:900–904. [PubMed] 24. Godinho SI, Maywood ES, Shaw L, Tucci V, Barnard AR, et al. The after-hours mutant reveals a role for Fbxl3 in determining mammalian circadian period. Science. 2007;316:897–900. [PubMed] 25. Siepka SM, Yoo SH, Park J, Song W, Kumar V, et al. Circadian mutant overtime reveals F-box protein FBXL3 regulation of cryptochrome and period gene expression. Cell. 2007;129:1011–1023. [PubMed] 26. Jin J, Cardozo T, Lovering RC, Elledge SJ, Pagano M, et al. Systematic analysis and nomenclature of mammalian F-box proteins. Genes Dev. 2004;18:2573–2580. [PubMed] 27. Graveley BR. Alternative splicing: increasing diversity in the proteomic world. Trends Genet. 2001;17:100–107. [PubMed] 28. Blencowe BJ. Alternative splicing: new insights from global analyses. Cell. 2006;126:37–47. [PubMed] 29. Ben-Dov C, Hartmann B, Lundgren J, Valcarcel J. Genome-wide analysis of alternative pre-mRNA splicing. J Biol Chem. 2008;283:1229–1233. [PubMed] 30. Kim E, Goren A, Ast G. Alternative splicing: current perspectives. Bioessays. 2008;30:38–47. [PubMed] 31. Forrest AR, Taylor DF, Crowe ML, Chalk AM, Waddell NJ, et al. Genome-wide review of transcriptional complexity in mouse protein kinases and phosphatases. Genome Biol. 2006;71:R5. [PubMed] 32. Pan Q, Saltzman AL, Kim YK, Misquitta C, Shai O, et al. Quantitative microarray profiling provides evidence against widespread coupling of alternative splicing with nonsense-mediated mRNA decay to control gene expression. Genes Dev. 2006;20:153–158. [PubMed] 33. Feillet CA, Mendoza J, Albrecht U, Pevet P, Challet E. Forebrain oscillators ticking with different clock hands. Mol Cell Neurosci. 2008;37:209–221. [PubMed] 34. Dardente H, Fortier EE, Martineau V, Cermakian N. Cryptochromes impair phosphorylation of transcriptional activators in the clock: a general mechanism for circadian repression. Biochem J. 2007;402:525–536. [PubMed] 35. Fonjallaz P, Ossipow V, Wanner G, Schibler U. The two PAR leucine zipper proteins, TEF and DBP, display similar circadian and tissue-specific expression, but have different target promoter preferences. EMBO J. 1996;15:351–362. [PubMed] 36. Schoenhard JA, Eren M, Johnson CH, Vaughan DE. Alternative splicing yields novel BMAL2 variants: tissue distribution and functional characterization. Am J Physiol Cell Physiol. 2002;283:C103–14. [PubMed] 37. Barnes JW, Tischkau SA, Barnes JA, Mitchell JW, Burgoon PW, et al. Requirement of mammalian timeless for circadian rhythmicity. Science. 2003;302:439–442. [PubMed] 38. Majercak J, Sidote D, Hardin PE, Edery I. How a circadian clock adapts to seasonal decreases in temperature and day length. Neuron. 1999;24:219–230. [PubMed] 39. DeBruyne JP, Weaver DR, Reppert SM. CLOCK and NPAS2 have overlapping roles in the suprachiasmatic circadian clock. Nat Neurosci. 2007;10:543–545. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||
Nature. 2002 Aug 29; 418(6901):935-41.
[Nature. 2002]Chronobiol Int. 2007; 24(2):195-213.
[Chronobiol Int. 2007]Cell. 2002 Jul 26; 110(2):251-60.
[Cell. 2002]J Biol Rhythms. 2005 Oct; 20(5):391-403.
[J Biol Rhythms. 2005]Proc Natl Acad Sci U S A. 1996 Apr 16; 93(8):3553-8.
[Proc Natl Acad Sci U S A. 1996]Chronobiol Int. 2007; 24(2):195-213.
[Chronobiol Int. 2007]Science. 2000 Apr 21; 288(5465):483-92.
[Science. 2000]Nat Rev Mol Cell Biol. 2007 Feb; 8(2):139-48.
[Nat Rev Mol Cell Biol. 2007]Cell. 2001 Dec 28; 107(7):855-67.
[Cell. 2001]Science. 2005 Aug 26; 309(5739):1390-4.
[Science. 2005]Curr Biol. 1999 Oct 21; 9(20):1177-9.
[Curr Biol. 1999]Curr Biol. 1999 Oct 21; 9(20):1180-2.
[Curr Biol. 1999]Science. 2007 May 11; 316(5826):900-4.
[Science. 2007]Cell. 2007 Jun 1; 129(5):1011-23.
[Cell. 2007]Genes Dev. 2004 Nov 1; 18(21):2573-80.
[Genes Dev. 2004]Trends Genet. 2001 Feb; 17(2):100-7.
[Trends Genet. 2001]Bioessays. 2008 Jan; 30(1):38-47.
[Bioessays. 2008]Cell. 2006 Jul 14; 126(1):37-47.
[Cell. 2006]J Biol Chem. 2008 Jan 18; 283(3):1229-33.
[J Biol Chem. 2008]Genome Biol. 2006; 7(1):R5.
[Genome Biol. 2006]Genes Dev. 2004 Nov 1; 18(21):2573-80.
[Genes Dev. 2004]Trends Genet. 2001 Feb; 17(2):100-7.
[Trends Genet. 2001]Bioessays. 2008 Jan; 30(1):38-47.
[Bioessays. 2008]Genes Dev. 2006 Jan 15; 20(2):153-8.
[Genes Dev. 2006]Cell. 2006 Jul 14; 126(1):37-47.
[Cell. 2006]J Biol Chem. 2008 Jan 18; 283(3):1229-33.
[J Biol Chem. 2008]Science. 2007 May 11; 316(5826):900-4.
[Science. 2007]Cell. 2007 Jun 1; 129(5):1011-23.
[Cell. 2007]Nature. 2002 Aug 29; 418(6901):935-41.
[Nature. 2002]Chronobiol Int. 2007; 24(2):195-213.
[Chronobiol Int. 2007]Cell. 2007 Jun 1; 129(5):1011-23.
[Cell. 2007]Biochem J. 2007 Mar 15; 402(3):525-36.
[Biochem J. 2007]Science. 2007 May 11; 316(5826):897-900.
[Science. 2007]Cell. 2007 Jun 1; 129(5):1011-23.
[Cell. 2007]Genes Dev. 2001 Apr 15; 15(8):995-1006.
[Genes Dev. 2001]Genes Dev. 2000 Mar 15; 14(6):679-89.
[Genes Dev. 2000]EMBO J. 1996 Jan 15; 15(2):351-62.
[EMBO J. 1996]Biochem J. 2007 Mar 15; 402(3):525-36.
[Biochem J. 2007]Am J Physiol Cell Physiol. 2002 Jul; 283(1):C103-14.
[Am J Physiol Cell Physiol. 2002]Science. 2003 Oct 17; 302(5644):439-42.
[Science. 2003]Neuron. 1999 Sep; 24(1):219-30.
[Neuron. 1999]Nat Neurosci. 2007 May; 10(5):543-5.
[Nat Neurosci. 2007]